

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
under the Securities Exchange Act of 1934**

March 10, 2020

Commission File Number 001-35203

---

**THERATECHNOLOGIES INC.**

(Translation of registrant's name into English)

---

2015 Peel Street, Suite 1100  
Montréal, Québec, Canada  
H3A 1T8  
(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  No

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  No

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_.

---

---

**THERATECHNOLOGIES INC.**

<b><u>Exhibit</u></b>	<b><u>Description</u></b>
99.1	Material Change Report Dated March 10, 2020

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

THERATECHNOLOGIES INC.

By: /s/ Jocelyn Lafond

Name: Jocelyn Lafond

Title: Vice President, Legal Affairs

Date: March 10, 2020

**MATERIAL CHANGE REPORT**  
**Regulation 51-102 Respecting Continuous Disclosure Obligations**  
**Form 51-102F3**

**ITEM 1 – NAME AND ADDRESS OF COMPANY**

Theratechnologies INC. (“Theratechnologies”)  
2015 Peel Street  
11th Floor  
Montreal, Québec  
Canada H3A 1T8

**ITEM 2 – DATE OF MATERIAL CHANGE**

March 2, 2020.

**ITEM 3 – NEWS RELEASE**

Theratechnologies issued a press release with respect to the material change described below on March 2, 2020 via CNW Telbec.

**ITEM 4 – SUMMARY OF MATERIAL CHANGE**

The Board of Directors of Theratechnologies appointed Paul Lévesque as the company’s President and CEO, effective April 6, 2020, replacing Luc Tanguay, who will be retiring on such date.

**ITEM 5 – FULL DESCRIPTION OF MATERIAL CHANGE****5.1 Full description of material change**

The Board of Directors of Theratechnologies appointed Paul Lévesque as the company’s President and CEO, effective April 6, 2020, replacing Luc Tanguay, who will be retiring on such date.

**5.2 Disclosure for restructuring transactions**

Not applicable.

**ITEM 6 – RELIANCE ON SUBSECTION 7.1(2) OR (3) OF NATIONAL INSTRUMENT 51-102**

Not applicable.

**ITEM 7 – OMITTED INFORMATION**

Not applicable.

**ITEM 8 – EXECUTIVE OFFICER**

For further information, contact Jocelyn Lafond, Vice President, Legal Affairs, and Corporate Secretary of Theratechnologies at (514) 336-7800.

**ITEM 9 – DATE OF REPORT**

March 10, 2020.